The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GpIIb/IIIa receptor blockade - Mascelli,M.A.; Lance,E.T.; Damaraju,L. (Circulation, 1998)